Factor VII (proconvertin)

Factor VII (proconvertin) Uses, Dosage, Side Effects, Food Interaction and all others data.

Coagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.

Human Factor VII complexes with tissue factor resulting in its activation to VIIa. It is the activated Factor VIIa that then binds to Factor X activating it to Factor Xa, as well as coagulation Factor IX is activated to Factor IXa. Factor Xa continues the coagulation cascade to eventually convert prothrombin to thrombin, which leads to the formation of a clot by converting fibrinogen to fibrin.

Factor VII (proconvertin)
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Factor VII (proconvertin)
Generic	Coagulation factor VII human
Coagulation factor VII human Other Names	Coagulation factor VII (human), Factor VII, Factor VII (proconvertin), Factor VII human, Human coagulation factor VII, Proconvertin, Serum prothrombin conversion accelerator
Type
Protein binding	Binds to coagulation factor X and IX and tissue factor.
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Factor VII (proconvertin) is a coagulation factor used to treat bleeding disorders such as hemophilia and Glanzmann's thrombasthenia.

May be administered in cases of uncontrolled bleeding. Factor VII alone can be used in the treatment of congenital hemophilia A or B, acquired hemophilia, congenital factor VII deficiency, and Glanzmann's thrombasthenia. Off label use in the treatment of refractory bleeding after cardiac surgery and warfarin related intracerebral hemorrhage. Brands for human factor VII are currently only in combination with other vitamin K coagulation factors and can be used to reverse vitamin K antagonist activity in patients with acute major bleeds or for urgent surgery/invasive procedures.

Factor VII (proconvertin) is also used to associated treatment for these conditions: Vitamin K antagonist induced major bleeding

How Factor VII (proconvertin) works

Factor VII is required in the extrinsic clotting cascade. When there is vascular damage tissue factor (TF) is released which then interacts with Factor VII resulting in the formation of the activated complex VIIa. Factor VIIa then continues to activate coagulation factors in the cascade until a clot is formed.